Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Effects of Fenofibrate in Burned Patients
NCT00361751Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- May 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fenofibrate in insulin resistance (IR) and hypertriglyceridemia (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Daily Plasma Glucose, Insulin stimulated glucose uptake and 2 more. Started May 2003; status: completed.
02
Drugs
fenofibrate
03
Conditions
insulin resistance (IR)hypertriglyceridemia
Beyond the preview
Go deeper on NCT00361751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361751.